Premium
Prognostic significance of human papillomavirus status and treatment modality in hypopharyngeal cancer
Author(s) -
Burbure Nina,
Handorf Elizabeth,
Ridge John A.,
Bauman Jessica,
Liu Jeffrey C.,
Giri Anshu,
Galloway Thomas J.
Publication year - 2021
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.26793
Subject(s) - medicine , hypopharyngeal cancer , stage (stratigraphy) , oncology , cancer , proportional hazards model , hazard ratio , larynx , survival analysis , human papillomavirus , surgery , confidence interval , paleontology , biology
Abstract Background Management of hypopharynx cancer is often extrapolated from larynx cancer. This report analyses treatment patterns and survival limited to hypopharynx cancer using the National Cancer Database (NCDB). Methods There are 9314 patients diagnosed with hypopharynx cancer between 2004 and 2016. The association between treatment modality and survival was analyzed using Kaplan–Meier survival curves and multivariable Cox regression. Results Five‐year overall survival ranged from 45% for stage I to 21% for stage IVB. Treatment modality did not influence survival in stage I/II. For stage III/IV, chemoradiation and surgery + adjuvant therapy were equivalent. Surgery yielded improved survival for T4 disease. Human papillomavirus (HPV)‐positive tumors were present in 21% and were associated with improved hazard ratio of death (0.60, p = <0.0001). Conclusions Survival is superior for T4 hypopharynx cancer managed with surgery, while treatment modality does not impact outcomes for other T‐stages. HPV‐positive tumors are associated with improved survival regardless of treatment.